Illumina's Q2 Revenue, R&D Spending More Than Double as Profit Jumps 37 Percent | GenomeWeb
NEW YORK (GenomeWeb News) — Illumina yesterday said second-quarter revenues and R&D spending more than doubled over last year as profits jumped 37 percent.
 
Total receipts for the three months ended June 30 increased to $84.5 million from $41.6 million year over year.
 
Product revenues jumped to $74.3 million from $36.4 million, while service and other revenue increased to $10.1 million from $4.8 million year over year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.